A U.S. jury on Tuesday found Bayer AG's glyphosate-based weed killer to be a "substantial factor" in causing a man's non-Hodgkin's lymphoma, allowing the trial to proceed into a second phase on liability and damages. » Read More
Altria shares dropped after the FDA Commissioner said a meeting last week with the company and its e-cigarette unit Juul was "difficult." » Read More
PolarityTE said the SEC subpoenaed it earlier this month for documents related to any promotion of the company or its securities, among other items. » Read More
A single pill can contain 35 inactive ingredients, some of which may cause adverse reactions in patients. » Read More
A California jury on Wednesday ordered Johnson & Johnson to pay $29 million to a woman who alleged that asbestos in the company's talcum-powder-based products, including Johnson's Baby Powder, caused her mesothelioma.
Health and Human Services Secretary Alex Azar takes heat on Capitol Hill over some of the Trump administration's proposed cuts in health care.
Aurora's executive chairman tells CNBC that the company's partnership with Nelson Peltz is one of many relationships it hopes to foster.
Start-up fertility establishments are a popular alternative to traditional fertility clinics — so much so that Wall Street is taking notice. But some physicians say they're concerned clients may not get all of the information they need.
Senate Finance Committee Chairman Chuck Grassley, R-Iowa., and Ron Wyden, D-Ore., the committee's ranking member, asked Cigna, CVS, Humana, OptumRx and Prime Therapeutics to testify on Capitol Hill on April 3.
Shares of major cannabis companies rallied Tuesday after New Jersey politicians outlined plans to legalize recreational marijuana use.
Some 228 measles cases were reported to the CDC in the U.S. between Jan. 1 and March 7, more than half of the 372 cases that were reported during all of 2018.
The biotech sector is on pace for its worst weekly decline since December, weighed down in part by uncertainty following this week's surprise announcement from FDA chief Scott Gottlieb that he will be stepping down next month.
The IBB, an ETF that tracks biotech's biggest players, was down more than 2 percent Wednesday, on pace for its worst day since Feb. 7, when it lost 2.5 percent.
The company said in an open letter to shareholders, its board of directors are "confident" the drugmakers acquisition of Celgene is the best path forward.
About 90 percent in the poll agree with Trump plans to require drug companies to include list prices in ads and to ease development of generic drugs.
The study, one of the largest examining the issue, challenges a push by some parents against vaccinating their children.
OxyContin-maker Purdue Pharma is exploring filing for bankruptcy amid thousands of lawsuits alleging the drug manufacturer contributed to the deadly opioid crisis sweeping the U.S., according to Reuters.
U.S. drugmaker Eli Lilly plans to sell a half-price version of its Humalog insulin injection, as it fends off criticism about rising drug prices.
Biogen said on Monday it will buy Nightstar Therapeutics for about $800 million in cash as the company looks to tap into a potentially lucrative gene therapy market.
Bristol-Myers Squibb is meeting with shareholders in Boston and New York as its $74 billion purchase of drugmaker Celgene is at risk of being derailed.